Nine years after the mutation was discovered, vemurafenib, a selective BRAF inhibitor, was approved by the United States Food and Drug Administration (FDA) as a first line single agent for the treatment of unresectable or metastatic malignant melanoma with a BRAF V600E mutation as detected by an FDA-approved test [5–8]. Here, BRAF is linked to metastatic melanoma.